Repligen/$RGEN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Repligen
Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category (about 55% of total revenue), while chromatography, proteins, and process analytics are 21%, 11%, and 13%, respectively. Customers in North America, Europe, and Asia Pacific contribute about 44%, 37%, and 19% of revenue, respectively.
Ticker
$RGEN
Sector
Primary listing
Employees
2,000
Headquarters
Website
Repligen Metrics
BasicAdvanced
$6.5bn
126.60
$0.91
1.09
-
Price and volume
Market cap
$6.5bn
Beta
1.09
52-week high
$175.77
52-week low
$100.99
Average daily volume
1.3m
Financial strength
Current ratio
9.202
Quick ratio
7.452
Long term debt to equity
31.658
Total debt to equity
32.659
Interest coverage (TTM)
2.32%
Profitability
EBITDA (TTM)
134.237
Gross margin (TTM)
53.14%
Net profit margin (TTM)
6.73%
Operating margin (TTM)
7.13%
Effective tax rate (TTM)
8.57%
Revenue per employee (TTM)
$380,000
Management effectiveness
Return on assets (TTM)
1.18%
Return on equity (TTM)
2.51%
Valuation
Price to earnings (TTM)
126.603
Price to revenue (TTM)
8.495
Price to book
3.09
Price to tangible book (TTM)
10.31
Price to free cash flow (TTM)
62.074
Free cash flow yield (TTM)
1.61%
Free cash flow per share (TTM)
1.856
Growth
Revenue change (TTM)
17.36%
Earnings per share change (TTM)
-317.20%
3-year revenue growth (CAGR)
0.12%
10-year revenue growth (CAGR)
24.14%
3-year earnings per share growth (CAGR)
-30.48%
10-year earnings per share growth (CAGR)
14.25%
What the Analysts think about Repligen
Analyst ratings (Buy, Hold, Sell) for Repligen stock.
Repligen Financial Performance
Revenues and expenses
Repligen Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs